Valneva SE
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Valneva SE, a specialty vaccine company, develops, manufactures and commercializes prophylactic vaccines targeting infectious diseases with significant unmet medical needs, including travelers' vaccines and candidates against Lyme disease, chikungunya, Shigella and Zika; its commercial portfolio comprises three proprietary products -- IXCHIQ, a single-shot chikungunya vaccine approved by the US FDA in 2023 and launched in the US in early 2024; IXIARO/JESPECT, an inactivated vaccine for Japanese encephalitis prevention; and DUKORAL, an oral vaccine against cholera and enterotoxigenic E. coli (ETEC) diarrhea -- marketed primarily to travelers, military personnel and individuals in endemic regions through direct sales in the US, Canada, UK and Nordics, and partnerships elsewhere. The company also leverages technologies such as the EB66 cell line and IC31 adjuvant through collaborations with pharmaceutical partners. Founded in 2013 through the merger of Intercell AG and Vivalis SA, Valneva SE maintains headquarters in Saint-Herblain, France, with manufacturing sites in Livingston, Scotland; Solna, Sweden; and Vienna, Austria; and operations across six countries employing over 700 people. Recent developments include a October 2025 debt refinancing agreement with Pharmakon Advisors for up to $500 million in non-dilutive financing, featuring an initial $215 million tranche to retire prior debt, extended maturities to 2030, lower interest rates and access to growth capital for business development; expansion of IXCHIQ access in Asia via partnership with Serum Institute of India; positive final Phase 2 results and ongoing Phase 3 VALOR trial for Lyme disease candidate VLA15 partnered with Pfizer, targeting regulatory submissions in 2026; a positive CHMP opinion for IXCHIQ in Europe; and nine-month 2025 revenues of €127.0 million with confirmed full-year guidance of €165-180 million total revenues. Valneva lists on Nasdaq (VALN) and Euronext Paris (VLA), with Pfizer holding approximately 8.1% equity tied to the Lyme partnership.
Company News
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
Valneva Provides Update on IXCHIQ® in the United Kingdom
Analyzing Valneva (NASDAQ:VALN) and Septerna (NASDAQ:SEPN)
Contrasting Absci (NASDAQ:ABSI) & Valneva (NASDAQ:VALN)
Valneva: The Lyme Royalty Transition Changes The Earnings Model
European Regulator Validates Pfizer and Valneva's Lyme Disease Vaccine Application
Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
Valneva SE (VALN) Q2 2026 Earnings Call Transcript
Valneva Q2 Earnings Call Highlights
Valneva publie ses résultats financiers du premier semestre 2026 et fait un point sur ses activités
Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates
Valneva to Report First Half 2026 Consolidated Financial Results on August 13, 2026
Valneva SE (VALN) Shareholder/Analyst Call Prepared Remarks Transcript
Valneva Announces Successful Outcome of its Annual General Meeting
Valneva Announces Availability of Documentation for its Annual General Meeting
Valneva annonce sa participation à des conférences investisseurs aux États-Unis et en Europe
Valneva to Participate at U.S. and European Investor Conferences in June
Valneva to Participate at U.S. and European Investor Conferences in June
Valneva Q1 Earnings Call Highlights